
TFF Pharmaceuticals TFFP
TFF Pharmaceuticals EV | TFFP
EV Jährlich TFF Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7.83 M | -14.6 M | 188 M | -28.3 M | -24.4 M | -9.1 M | 1.83 K | - | - | - | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 188 M | -28.3 M | 17.1 M |
EV anderer Aktien in der Pharmaeinzelhändler
| Name | EV | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Armata Pharmaceuticals
ARMP
|
599 M | $ 3.06 | 2.68 % | $ 111 M | ||
|
Celldex Therapeutics
CLDX
|
2.07 B | $ 27.36 | -2.15 % | $ 1.82 B | ||
|
Cellectis S.A.
CLLS
|
522 M | $ 0.9 | -9.7 % | $ 90.3 M | ||
|
Lineage Cell Therapeutics
LCTX
|
450 M | $ 0.78 | -4.87 % | $ 179 M | ||
|
Edesa Biotech
EDSA
|
497 K | $ 2.01 | -7.59 % | $ 11.4 M | ||
|
Eli Lilly and Company
LLY
|
933 B | $ 1 345.4 | -0.44 % | $ 1.21 T | ||
|
Collegium Pharmaceutical
COLL
|
2.52 B | $ 24.73 | -1.9 % | $ 783 M | ||
|
Evogene Ltd.
EVGN
|
1.49 M | $ 0.32 | 1.02 % | $ 2.52 M | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
119 M | $ 2.05 | -15.81 % | $ 27.3 M | ||
|
Forte Biosciences
FBRX
|
280 M | $ 76.99 | 0.03 % | $ 997 M | ||
|
Curis
CRIS
|
18.9 M | $ 0.44 | -6.31 % | $ 5.79 M | ||
|
CorMedix
CRMD
|
276 M | $ 5.25 | 4.23 % | $ 378 K | ||
|
Larimar Therapeutics
LRMR
|
354 M | $ 3.07 | -4.66 % | $ 255 M | ||
|
Champions Oncology
CSBR
|
102 M | $ 4.34 | -1.36 % | $ 60 M | ||
|
Mesoblast Limited
MESO
|
12.6 B | $ 10.9 | -2.5 % | $ 13.2 B | ||
|
Mirum Pharmaceuticals
MIRM
|
5.68 B | $ 96.15 | 0.67 % | $ 4.83 B | ||
|
MannKind Corporation
MNKD
|
1.76 B | $ 3.85 | -2.66 % | $ 1.18 B | ||
|
Dyadic International
DYAI
|
35.6 M | $ 0.29 | -6.53 % | $ 10.5 M | ||
|
Merck & Co.
MRK
|
296 B | $ 133.34 | 0.4 % | $ 334 B | ||
|
Moderna
MRNA
|
20.5 B | $ 195.25 | -2.05 % | $ 76 B | ||
|
NuCana plc
NCNA
|
85.3 B | $ 0.75 | 4.39 % | $ 8.42 B | ||
|
Novartis AG
NVS
|
369 B | $ 150.51 | -0.47 % | $ 292 B | ||
|
Puma Biotechnology
PBYI
|
434 M | $ 7.05 | -1.05 % | $ 353 M | ||
|
Fulcrum Therapeutics
FULC
|
454 M | $ 3.69 | -0.67 % | $ 281 M | ||
|
PDS Biotechnology Corporation
PDSB
|
19.6 M | $ 0.79 | -2.58 % | $ 36.6 M | ||
|
Geron Corporation
GERN
|
1.33 B | $ 0.87 | -4.76 % | $ 580 M | ||
|
Pharming Group N.V.
PHAR
|
11.8 B | $ 11.54 | -5.18 % | $ 7.95 B | ||
|
Phathom Pharmaceuticals
PHAT
|
1.55 B | $ 4.65 | -8.46 % | $ 339 M | ||
|
Genmab A/S
GMAB
|
1.41 B | $ 50.36 | -1.93 % | $ 3.26 B | ||
|
Gossamer Bio
GOSS
|
365 M | $ 10.69 | -4.81 % | $ 2.44 B | ||
|
Grifols, S.A.
GRFS
|
16.3 B | $ 8.14 | -0.73 % | $ 5.53 B | ||
|
Liquidia Corporation
LQDA
|
3.04 B | $ 54.39 | -3.96 % | $ 4.68 B | ||
|
GlaxoSmithKline plc
GSK
|
258 B | $ 47.8 | -0.05 % | $ 194 B | ||
|
MediciNova
MNOV
|
42.4 M | $ 1.3 | 2.36 % | $ 63.8 M | ||
|
PTC Therapeutics
PTCT
|
7.68 B | $ 56.23 | -3.59 % | $ 4.47 B | ||
|
Pulmatrix
PULM
|
5.07 B | $ 1.24 | -12.34 % | $ 4.53 B | ||
|
InflaRx N.V.
IFRX
|
60.9 M | $ 1.05 | -3.67 % | $ 70.7 M | ||
|
Immunome
IMNM
|
1.28 B | $ 15.69 | -5.54 % | $ 1.37 B | ||
|
Immuron Limited
IMRN
|
230 M | $ 0.9 | 5.87 % | $ 208 M | ||
|
Incyte Corporation
INCY
|
18.2 B | $ 114.5 | -1.19 % | $ 22.4 B | ||
|
INmune Bio
INMB
|
12.3 M | $ 0.82 | -8.41 % | $ 20.3 M | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
153 B | $ 14.88 | 0.24 % | $ 12.4 B | ||
|
Regeneron Pharmaceuticals
REGN
|
87.4 B | $ 920.38 | -0.22 % | $ 96.3 B | ||
|
Ionis Pharmaceuticals
IONS
|
15.6 B | $ 26.58 | -2.37 % | $ 4.25 B | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
434 M | $ 1.06 | -10.92 % | $ 48.4 M | ||
|
Ironwood Pharmaceuticals
IRWD
|
-115 M | $ 4.68 | -0.53 % | $ 757 M | ||
|
Kala Pharmaceuticals
KALA
|
-3.43 M | $ 2.73 | -9.61 % | $ 22.2 M | ||
|
Intellia Therapeutics
NTLA
|
791 M | $ 10.02 | 5.24 % | $ 1.09 B | ||
|
Adagene
ADAG
|
176 M | $ 1.8 | -10.56 % | $ 106 M | ||
|
Denali Therapeutics
DNLI
|
2.34 B | $ 18.43 | 1.29 % | $ 3.18 B |